Evidence map›Paper›PMID 42321163›Full record

ArticleNature communications2026

USP24 is a cross-reactive DUB targeting MOV10 to regulate IFN-I production.

Rishov Mukhopadhyay, Simeon D Draganov, Timo Oosenbrug, Jimmy J L L Akkermans, Marjolein Kikkert, Klaus-Peter Knobeloch, Günter Fritz, María Guzmán, Sonia Zuñiga, Robbert Q Kim and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rishov MukhopadhyayDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Simeon D DraganovChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-8695-3499
Timo OosenbrugDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7533-0595
Jimmy J L L AkkermansDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
Marjolein KikkertDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-5779-7386
Klaus-Peter KnobelochInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID 0000-0003-1587-1944
Günter FritzDepartment of Cellular Microbiology, University of Hohenheim, Stuttgart, Germany.ORCID 0000-0002-4571-8812
María GuzmánDepartment of Molecular and Cell Biology, National Center for Biotechnology (CNB-CSIC), Madrid, Spain.ORCID 0000-0002-3866-5222
Sonia ZuñigaDepartment of Molecular and Cell Biology, National Center for Biotechnology (CNB-CSIC), Madrid, Spain.ORCID 0000-0003-2549-6826
Robbert Q KimDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1834-8673
Annemarthe G van der VeenDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9324-3404
Benedikt M KesslerChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.ORCID 0000-0002-8160-2446
Adán Pinto-FernándezChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.ORCID 0000-0003-1693-9664
Paul P GeurinkDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. p.p.geurink@lumc.nl.ORCID 0000-0003-1849-1111
Aysegul SapmazDepartment of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands. a.sapmaz@lumc.nl.ORCID 0000-0003-3942-7602

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The type I Interferon (IFN-I)-induced ubiquitin-like modifier Interferon-Stimulated Gene 15 (ISG15) plays a crucial role in the innate immune response against viral infections. ISG15 is conjugated to target proteins by an enzymatic cascade, called ISGylation. While ubiquitin-specific protease 18 (USP18) serves as the major deISGylase counteracting ISG15 conjugation, ISG15 cross-reactive deubiquitylating enzymes (DUBs) have also been reported. Here, we identify USP24 as an ISG15 cross-reactive DUB through activity-based protein profiling. USP24 processes pro-ISG15 and ISG15-linked substrates in vitro, and its depletion increases ISG15 conjugates following interferon stimulation in cells without altering canonical IFN-I signaling. USP24 knockout cells show increased IFN-β and ISG expression upon activation of cytosolic RNA sensing via viral mimicry. Proteomic analysis identifies RNA helicase Moloney leukemia virus 10 (MOV10) as a specific target of USP24 for deISGylation. Our data revealed that ISGylation of MOV10 promotes MOV10 interaction with IFIT3 and enhances IFN-β production/secretion in response to viral stimuli. This process is negatively regulated by USP24, which directly deISGylates MOV10. Our data highlight USP24's role in modulating ISGylation and IFN-I production, suggesting USP24 as a potential therapeutic agent for infectious and inflammatory diseases.

Indexed as

CytokinesInterferon-betaInterferon Type IRNA HelicasesUbiquitinsUbiquitin ThiolesteraseAnimalsHEK293 CellsHumansImmunity, InnateMiceSignal TransductionCytokinesInterferon-betaInterferon Type IISG15 protein, humanRNA HelicasesUbiquitinsUbiquitin Thiolesterase

Identifiers

PMID42321163
PMCPMC13433998

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.